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Abstract: 
Background: The insulin-like growth factor (IGF) system is composed of ligands and receptors which 
regulate cell proliferation, survival, differentiation and migration. Some functions are regulated via 
intracellular signaling cascades, others by involvement of the extracellular milieu, including binding 
proteins and other extracellular matrix proteins. However, understanding of their functions and the 
exact nature of these interactions remains incomplete.  
Methods: IGF-I was PEGylated at its lysine sites - K27, K65 and K68. Binding of PEG-IGF-I to the 
IGFBPs was analyzed using BIAcore and its ability to activate the IGF-IR was assessed using IGF-IR 
phosphorylation assay. Furthermore, functional consequences of PEGylating the lysine residues of 
IGF-I was investigated using cell viability and cell migration assays. In addition, particular 
downstream signaling pathways regularly implicated in these mechanisms were also dissected using 
phospho-AKT and phospho-ERK1/2 assays. 
Results: In this study, IGF-I specifically PEGylated at lysine 27 (PEG-K27), 65 (PEG-K65) or 68 
(PEG-K68) were employed. Receptor phosphorylation was only reduced by 2-fold with PEG-K65 and 
PEG-K68 over all the time points tested, and as observed in two cell types, 3T3 fibroblasts and MCF-
7 breast cancer cells. PEGylation at K27 resulted in a much larger effect, with more than 10-fold 
lower activation for 3T3 fibroblasts and a ~3 fold reduced IGF-IR activation for MCF-7 breast cancer 
cells over 15 minutes. In addition, all PEG-IGF-I variants demonstrated a ten-fold reduction in the 
association rate to IGF binding proteins (IGFBPs). Functionally, all PEG variants completely lost 
their ability to induce cell migration in the presence of IGFBP-3/vitronectin (VN) complexes as 
compared to IGF-I; in contrast, cell viability was fully preserved. Further investigations into the 
downstream signaling pathways revealed that the PI3-K/AKT pathway was preferentially affected 
upon treatment with the PEG-IGF-I variants compared to the MAPK/ERK pathway. 
Conclusion: PEGylation of IGF-I has an impact on cell migration but not cell viability. 
General significance: PEG-IGF-I may differentially modulate IGF-I mediated functions that are 
dependent on its interaction with its receptor as well as key extracellular proteins such as VN and 
IGFBPs. 
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1. Introduction 
Insulin-like growth factor-I (IGF-I) received its name due to structural similarities with insulin and is 
part of a complex system including six high affinity IGF binding proteins (IGFBPs) and two 
membrane bound IGF receptors [reviewed in 1]. IGF-I plays a critical role in normal human growth, 
development and wound healing [2-4]. Dysregulation of the IGF-I signaling system is implicated in 
non-healing wounds, progressive scarring and different human cancers [3, 5-7]. These are diseases 
which drastically reduce the quality and length of life, and worldwide account for huge medical costs 
and lost productivity. In view of this, the IGF signaling axis has been extensively studied due to its 
potential as a therapeutic target by not only increasing but also blocking its action depending on the 
relevant disease conditions [8].  
IGF-I mediates its cellular effects by signaling through the type-I IGF receptor (IGF-IR). The 
emphasis of drug development targeting the IGF signaling axis is evident from the fact that more than 
70 clinical trials are being undertaken wherein 30 candidate drugs are currently being tested targeting 
the IGF-I axis in a variety of human malignancies [reviewed in 9, 10-13]. Much of the 
abovementioned data suggests that the IGF system is a promising target in cancer therapy in 
combination with other existing chemotherapy techniques. 
Conversely, increased IGF-I activity has been implicated to be therapeutically relevant in other 
disease conditions. For example, IGF-I is produced by the wound fibroblasts and acts on both the 
keratinocytes and fibroblasts during the wound-healing process. Previous research with diabetic skin 
and foot ulcers has shown that there is a lack of IGF-I expression within the basal layer and 
fibroblasts of these ulcers and this may relate to the delayed wound-healing process observed in 
diabetic patients [14]. Moreover, in vitro and in vivo data suggests a possible role for this growth 
factor system in skin through regulating cell survival pathways that repair damage caused by harmful 
irradiation, such as ultra violet rays [15-17]. This IGF-I-mediated augmentation of cell survival has 
also been demonstrated experimentally to coincide with the recruitment of DNA repair machinery, 
inhibiting intracellular apoptotic factors and temporary arrest of the cell cycle [18, 19]. IGF-I has been 
long known for its growth promoting effects, especially during muscle growth and regeneration [20]. 
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In fact, a decline in levels of IGF-I has been associated with skeletal muscle disorders such as 
muscular dystrophy [21]. Indeed, recombinant human IGF-I is being developed as a therapy for short 
stature caused by IGF deficiency and also for diabetes mellitus [22]. In light of this evidence, the IGF 
system is emerging as a promising new target for several disease states, wherein replenishing IGF-I 
would better patient’s prognostic outcomes.  
Methods used to modify IGF-I in order to increase its bio-availability have long been investigated in 
disease states where IGF-I is being therapeutically used. One way of increasing the bio-availability is 
to covalently modify proteins with polyethylene glycol (PEG). This has proven to be a useful method 
to extend the circulating half-lives of proteins in the body [23-27]. Other advantages of protein 
PEGylation are increased water solubility and a decrease in protein immunogenicity [28]. Indeed, 
IGF-I was PEGylated in order to increase its bio-availability [29], however it remains unknown how 
the addition of a large PEG residue alters the different biological functions of IGF-I. In this 
manuscript, we characterize and discuss the binding properties of PEGylated IGF-I variants, with 
specific emphasis on two functional readouts: cell viability and cell migration. This is of interest 
especially for therapeutic purposes wherein PEGylation of IGF-I can be considered as a useful tool to 
provide improved and consistently stable IGF-I within the circulation and/or the tissue. In addition, 
this also enabled us to decipher the functional significance of lysine residues within IGF-I , since PEG 
residues get preferentially added to NH- side chains of the lysine residues of IGF-I. 
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2. Methods 
2.1 PEGylation of IGF-I 
Recombinant human insulin-like growth factor (rhIGF-I) was purchased from PeProTech (Rocky Hill, 
NJ, USA) via Cell Concepts (Umkirch, Germany). The PEG reagent was obtained from Nektar Ltd. 
(San Carlos, CA, USA). IGF-I isomers with PEGylation at a single site (monoPEG-IGF-I) were 
produced in-house (Roche, Basel, Switzerland). MonoPEG-IGF-I was prepared by the conjugation of 
lysine -amino groups at the surface or on the N-terminus of the IGF-I molecule with an activated 
branched PEG moiety of 40 kDa molecular weight. The PEGylation reaction mixture contained 
rhIGF-I and 40 kDa PEG-NHS reagent at 1:1.5 molar ratio in 50 mM sodium borate buffer, pH 9.0. 
The reaction was performed for 30 min at 4°C. Based on the average molecular weight of 44 kDa for 
the PEG moiety used and a molecular weight of 7.6 kDa for IGF-I, the calculated average molecular 
weight for monoPEG-IGF-I was expected to be around 51.6 kDa. For generating pure K68 PEGylated 
IGF-I, the process described by Metzger et al. [29] was employed. 
2.2 Analysis of positional PEG-IGF-I isomers 
A purification scheme with a preparative strong-cation exchange column (TOSOH-BIOSEP, SP-
5PW, 30 mm i.d. and 75 mm length) was used to prepare pure monoPEG-IGF-I isoforms. The buffer 
system consisted of 7.5 mM sodium acetate, 10% ethanol and 1% diethylene glycol, adjusted to pH 
4.5 (buffer A) and 20 mM potassium phosphate, 10% ethanol and 1% diethylene glycol, adjusted to 
pH 6.5 (buffer B).The column was pre-equilibrated with 25% buffer B. After loading the PEG-IGF-I 
samples, the column was washed with 35% buffer B, followed by an ascending linear gradient to 65% 
buffer B to separate the isomers. For the elution of the non-PEGylated IGF-I the system was switched 
to modified buffer B at pH 8.0. The flow rate was 8 mL/min and the detection was performed at 218 
nm. The resulting protein samples were collected manually and stored at -20°C until further analysis. 
An analytical strong-cation exchange column (TOSOH-BIOSEP, SP-NPR, 2.5 µm particle size, 4.6 
mm diameter, 3.5 cm length) was used to investigate the purity of the separated positional isomers. 
For this analytical column, the same mobile phases were employed as used in the preparative column 
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but with reduced flow rate and running time. The protein concentration of the monoPEG-IGF-I 
isomers was determined by spectrophotometry, based on the 280 nm absorption (=0.584) of the 
monoPEG-IGF-I. 
Individual monoPEG-IGF-I isomers were analyzed by 4-12% Tris-glycine SDS-PAGE under non-
reducing or reducing conditions. The proteins were fixed and stained using the SimplyBlue SafeStain 
(Invitrogen, Basel, Switzerland). For PEGylation of site-specific variants, recombinant human IGF-I 
(rhIGF-I) was PEGylated with 40 kDa branched PEG (Nektar Therapeutics), and the isoforms 
PEGylated at K27, K65 and K68 were separated and purified as recently described (patent 
US20100210547, see also Metzger et al. [29]. PEG isomers were always used at equimolar protein 
concentrations of rhIGF-I.  
2.3 Cell Culture 
The NIH-3T3 mouse fibroblasts and MCF-7 human breast carcinoma cell lines were obtained from 
the American Type Culture Collection (ATCC, Manassas, VA). NIH-3T3 cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) medium (Invitrogen) and MCF-7 cells were 
maintained in DMEM/Ham’s F12 (1:1) medium (DMEM/F12) containing 15 mM HEPES. For 
normal growth and maintenance 10% FCS, 1% Penicillin+Streptomycin (Invitrogen) and 0.01% 
Gentamicin (Invitrogen) was added to the media. 
2.4 IGF-IR phosphorylation assay 
NIH-3T3 cells stably transfected with human IGF-IR were used for these experiments between 
passages 2 and 4. Cells were cultivated either in uncoated 24- or 96- well plates and grown in DMEM 
with 10% FCS at 37 °C, 5% CO2 until 70% confluence. Subsequently, cells were serum-starved 
overnight (16 hours) and incubated with rhIGF-I, PEG-K27, PEG-K65 or PEG-K68 for 15 minutes. 
Cells were fixed with 4% paraformaldehyde for 30 minutes for in-cell analysis of IGF-IR 
phosphorylation. Fixed cells were blocked, permeabilized with 2% goat serum + 0.1%Triton X-100 
and incubated with mouse anti-phosphotyrosine (4G10, 1:1000; Upstate) and rabbit anti-IGF-IR (C-
20, 1:1000; Santa Cruz) primary antibodies. These were subsequently labeled with anti-mouse 
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Alexa680 (1:10000; Molecular Probes) and anti-rabbit-IRDye800 secondary antibodies (1:10000; 
Jackson). Fluorescence detection was performed with the Odyssey imaging system (Licor 
Biosciences). From digital images, pixel intensity was quantified and dose response curves were 
analyzed using GraphPad Prism software. Phosphotyrosine levels were normalized to IGF-IR values 
obtained from the same regions of interest. Experiments were performed in duplicate and repeated 3 
times to obtain 6 independent investigations per dose. Data were expressed as mean ± standard error 
(SEM). 
2.5 Cell signaling and Western immunoblotting 
For cell signaling experiments, MCF-7 cells were cultivated in 6- well plates and grown in DMEM/F-
12 with 10% FCS at 37 °C, 5% CO2  until 70% confluence. Subsequently, cells were serum-starved 
for 4 hours and incubated with rhIGF-I, PEG-K27, PEG-K65 or PEG-K68 for 15 minutes, 1 hour and 
3 hours. Total protein was extracted from cell lysates using RIPA buffer (Sigma-Aldrich) containing 
protease inhibitor (Pierce) and phosphatase inhibitor cocktail (Pierce). Twenty microgram protein was 
resolved on NuPAGE® gradient SDS-PAGE gels (4%-12%) (Life Technologies) and transferred onto 
polyvinylidene fluoride (PVDF) membranes (Pall Corporation; Cheltenham, VIC, Australia). The 
membranes were probed with anti-phospho ERK1/2 (1:1,000), anti-phospho AKT (1:1,000) and anti-
phospho IGF-IRβ (1:1,000) antibodies. The membranes were subsequently incubated with HRP-
linked secondary antibody (1:5,000) and developed using an automated chemiluminescence detector 
(Molecular Imager® ChemiDoc™ XRS+ system; Bio-Rad). The membranes were stripped using 
Restore™ Plus stripping buffer (Pierce; Scoresby, Australia) and the total protein levels were 
validated for equal loading using the respective anti-ERK1/2, anti-AKT or anti-IGF-IR antibodies. 
From the digital images of anti-IGF-IR immunoblots, pixel intensity was quantified using the ImageJ 
software. 
2.6 BIAcore analysis of IGF-I binding protein interaction 
BIAcore technology exploits surface plasmon resonance (SPR) as the detection principle to monitor 
the label-free interaction between biomolecules in real time. One of the interacting partners is 
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immobilized on the sensor chip surface while the soluble ligand is floating over the surface at a 
constant rate, which permits calculation of the binding constants kon and koff. For the initial calibration 
experiments, preliminary functional tests were performed to confirm that the binding affinity was 
independent of the immobilization technique and the nature of the protein used. To investigate the 
interaction of monoPEG-IGF-I isomers with the IGFBPs, IGFBP-1, -2, -3, -4, -5 or -6 were 
immobilized by amide coupling on a CM5 BIAcore sensor chip. The carboxylic groups on the sensor 
chip were then activated using a mixture of N-hydroxysuccinimide and carbodiimide. The amount of 
immobilized protein was controlled via the contact time. 1200 - 1800 response units (RU) were 
immobilized corresponding approximately to a protein density of 1.2 - 1.8 ng/mm
2
. For the binding 
experiments, a HEPES running buffer was used consisting of 10 mM HEPES, 150 mM NaCl, 3 mM 
EDTA, and 0.005% polysorbate 20, adjusted to pH 7.4. The immobilized IGFBPs were subsequently 
contacted with rhIGF-I and monoPEG-IGF-I at various concentrations (1.25 - 100 nM). The binding 
data was obtained by fitting the time dependent response curves based on the simple kinetic model of 
a 1:1 complex formation. From this fit, kon and koff values as well as the ratio of koff/kon (represented as 
KDkin) were obtained. 
2.7 Cell migration assay 
The Roche xCELLigence Real-Time Cell Analyzer (RTCA) Dual Plate (DP) instrument was used to 
monitor the migration of MCF-7 cells seeded in the upper chamber to the bottom chamber through 8-
µm pore-sized membranes. The cell migration was investigated and assessed in response to the PEG-
IGF-I isomers (given as VN:IGFBP-3:PEG-IGF-I complex). Lower chambers and the under-surface 
of the membranes of the xCELLigence CIM Plate-16 were either pre-coated with 160 µl protein 
solutions (VN, 1 µg/ml; IGFBP-3, 300 ng/ml; PEG-IGF-I, 100 ng/ml) with unbound proteins removed 
with washing (substrate-bound setup) or proteins attached allowed to remain in solution (solution-
phase setup) in serum-free media (SFM) + 0.05% BSA. The background impedance of the plate was 
measured before seeding the cells. Sub-confluent MCF-7 cells split 1:1 a day prior were serum-
starved for 4 hours and were harvested. A cell suspension containing 5 x 10
4
 cells in 100 µl SFM + 
0.05% BSA was seeded onto the upper-chamber on the wells. Changes in impedance at the gold 
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microelectrodes covering the under-surface of the membranes resulting from cell migration were 
measured and recorded every 15 minutes over 15 hours. Rate of migration was calculated by the 
RTCA 1.2 software based on the average slope of the curve. Statistical analysis was performed using 
ANOVA and Dunnet’s post-hoc test by comparing all experimental groups against the control. 
2.8 Cell viability assay 
Sub-confluent MCF-7 cells were split 1:1 24 hours prior to performing the viability assay to assist 
with cell synchrony. The cells were serum-starved for 4 hours before seeding 5 x 10
3
 cells suspended 
in 100 µL SFM + 0.05% BSA into 96-well plates. IGF-I, recombinant and PEGylated, at desired 
concentrations was added to the respective wells. The cells were incubated for 72 hours at 37°C, 5% 
CO2 and cell viability including their proliferation was assessed using the CellTiter 96
® 
AQueous one 
solution cell proliferation Assay (MTS) (Promega). The MTS assay is a colorimetric method for 
determining the number of viable cells in proliferation, cytotoxicity or chemosensitivity assays. The 
reagent contains a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron coupling reagent 
(phenazine ethosulfate; PES). After 72 hours, 20 µL of the MTS reagent was added into each well, 
and the cells were then incubated for 2 hours at 37 °C, 5% CO2 to allow for colour development. The 
absorbance was recorded at 490 nm using a 96-well plate reader (Benchmark Plus, Bio-Rad). The 
quantity of formazan product as measured by the amount of 490 nm absorbance is directly 
proportional to the number of viable cells in culture [30]. Wells containing SFM + 0.05% BSA 
medium only were used as blanks. 
 
3. Results 
3.1 Chromatographical separation of monoPEG-IGF-I isomers 
In human IGF-I, putative PEGylation sites are the three IGF-I lysine sites, i.e. lysines 27, 65 and 68 
(K27, K65 and K68, respectively). Under the applied conditions, we thus generated three PEGylated 
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IGF-I monomeric isomers. A strong-cation high pressure liquid chromatography method (IEC-HPLC) 
was developed for the separation of PEG-IGF-I isomers based on their local charge differences. A 
preparative elution profile of 5 mg PEG-IGF-I is shown in Figure 1A, with 5 major protein peaks 
(labelled 0-4) depicted. Subsequent analytical IE-HPLC demonstrated that all protein peaks had a 
purity of >99%. SDS-PAGE was then performed under both non-reducing and reducing conditions to 
evaluate potential cross-linking of different IGF-I molecules through intermolecular disulfide bridges. 
Both reducing and non-reducing conditions yielded similar results indicating that no significant 
amount of the protein was abnormally cross-linked. Protein in peak 0 had an apparent molecular 
weight of >100 kDa whereas the major bands detected in protein peaks 1-3 were at ~70 kDa 
(presumably monoPEGylated isomers), additionally protein in peak 4 was detected at ~7 kDa (Figure 
1B). The discrepancy between the expected molecular weight for monoPEG-IGF-I (51.6 kDa) and the 
apparent size of ~70 kDa is explained by the larger hydrodynamic volume of PEG considerably 
slowing the electrophoretic motility. Subsequently, individual isomers were characterised by Edman 
degradation. Protein in peak 0 consisted of di- and oligo PEG-IGF-I, suggested by the high molecular 
weight band in the gel (Figure 1B), protein in peak 1 was identified as PEG-K27, protein in peak 2 
was identified as PEG-K65, and peak 3 consisted of PEG-K68 with 80 - 100% purity, and protein in 
peak 4 was identified as native IGF-I (Edman analytical data not shown).  
3.2 IGF-IR phosphorylation by rhIGF-I and PEG-IGF-I isomers 
NIH-3T3 cells stably expressing the human IGF-IR were stimulated with rhIGF-I, PEG-K27, PEG-
K65 and PEG-K68 for 15 min at 37 °C and receptor activation was analyzed. Dose responses were 
fitted to a Hill binding model (Figure 2A). For rhIGF-I, an EC50 of 11.7 nM was obtained. The Hill 
coefficient of 1.605 indicated a moderate cooperative mode of activating the IGF-IR. PEG-K27 
induced IGF-IR phosphorylation only with an EC50 of 128.9 nM, no saturation at high doses, and a 
Hill coefficient of 0.429. PEG-K65 and PEG-K68 similarly activated the IGF-IR with slightly reduced 
EC50 values compared to rhIGF-I (25.5 nM and 23.0 nM, respectively) and regular Hill coefficients 
(0.950 and 0.961, respectively). These data suggest that both PEG-K65 and PEG-K68 activate the 
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receptor, albeit with a ~2-fold loss of potency compared to rhIGF-I, whereas PEGylation at K27 
further reduces the specific activation of IGF-IR. 
In addition to the IGF-IR dose response study outlined above, IGF-IR activation in response to rhIGF-
I and PEG-IGF-I isomers was also investigated in a time course experiment over 15 minutes, 1 hour 
and 3 hours (Figure 2B). Over 15 minutes, PEG-K27 demonstrated reduced ability (3-fold reduction) 
to stimulate IGF-IR phosphorylation when compared to rhIGF-I (Figure 2B). Furthermore, PEG-K65 
and PEG-K68 demonstrated 2-fold reduced IGF-IR activation (Figure 2B). With respect to 1 hour and 
3 hour time points, all the PEG-IGF-I isomers demonstrated a 2-fold reduction in IGF-IR activation 
when compared to the sustained activation of IGF-IR by rhIGF-I over these time points considered 
(Figure 2B).  
3.3 Binding of rhIGF-I and PEG-IGF-I to IGFBPs 
Kinetic properties of the interaction of rhIGF-I and PEG-IGF-I with IGFBPs were directly analyzed 
by BIAcore. Data for rhIGF-I and PEG-K68 were reproduced with permission from Metzger et al. 
2011, for better illustration. Compared to rhIGF-I, all PEG-IGF-I isomers showed very similar (~10-
fold lower) Kd values (Figure 3). The shift in Kd was mainly parallel to the y-axis, since the changes 
mostly originated from a reduction in kon, with koff being largely unaffected (Figure 3). PEGylation at 
either site led to a reduction in kon, as all PEG isomers clustered around a Kd value for each individual 
IGFBP (indicated by dashed circles; Figure 3). The data indicate that PEGylation leads to a loss of 
affinity towards IGFBPs by mainly affecting kon and seems to be independent of the site of 
PEGylation. 
3.4 Cell migration in response to substrate-bound rhIGF-I and PEG-IGF-I isomers 
Previous studies published by our collaborators [5, 31] have demonstrated that rhIGF-I, in 
combination with IGFBP-3 and the extracellular matrix (ECM) protein vitronectin (VN), stimulates 
epithelial cell migration. PEGylated IGF-I isomers were tested in a similar fashion to assess their 
ability to stimulate MCF-7 cell migration in the presence of IGFBP-3 and VN. Serum starved MCF-7 
cells suspended in serum-free medium were seeded onto the xCELLigence CIM Plate-16 pre-coated 
12 
 
on the under-surface with VN (13 nM) in combination with IGFBP-3 (11 nM) and either rhIGF-I or 
PEG-IGF-I isomers PEG-K27, PEG-K65 and PEG-K68, each at 100 ng/ml (13 nM). Migration was 
assessed in real-time, with the impedance changes (denoted as Cell Index units) occurring whilst 
migration of cells through the 8 µm-pore membrane measured every 15 minutes over 15 hours. While 
VN only control treatments stimulated substantial cell migration, the addition of rhIGF-I in 
combination with IGFBP-3 roughly doubled the migration rate (Figure 4A). In contrast, all PEG-IGF-
I isomers supplemented with VN+IGFBP-3 did not stimulate migration further than the control 
treatments without IGF-I. Quantitative analysis revealed a migration rate of 0.052 units per 15 h under 
control conditions (VN only) and 0.102 units per 15 h for rhIGF-I (p<0.001; Figure 5B). No change of 
migration rate was obtained with PEG-K27 (0.053 units per 15 h), PEG-K65 (0.064 units per 15 h) 
and PEG-K68 (0.068 units per 15 h) (Figure 4B). These data indicate that PEGylation of IGF-I at 
lysine sites in general leads to a loss in its potential to stimulate epithelial cell migration in the 
presence of IGFBP-3 and VN.  
3.5 Cell migration in response to rhIGF-I and PEG-IGF-I isomers suspended in solution 
Studies involving PEG-IGF-I isomers bound to IGFBP-3 and VN demonstrated a reduction in MCF-7 
breast cell migration (Figure 4). The assay setup consisted only of IGF-I that remained pre-bound to 
IGFBP-3 and VN, with unbound IGF-I being removed with washing. Since PEG-IGF-I was shown to 
have reduced affinity to IGFBP-3, the decreased migration may have been due to IGF-I being unable 
to bind IGFBP-3 efficiently. To investigate if alterations in IGFBP-3/IGF-I interactions lead to 
reduced cell migration, a solution-phase setup was employed wherein IGF-I (recombinant or 
PEGylated) at concentrations identical to that used in substrate-bound setup was added to the bottom 
chambers of the xCELLigence plate and allowed to remain in solution throughout the entire duration 
of the assay. This was in contrast to the previous substrate-bound setup wherein only IGF-I captured 
to IGFBP-3 remained in the chambers. Such an approach allowed us to isolate interactions of IGF-I 
with its receptor and to investigate the subsequent effects on cell migration. VN was added along with 
IGF-I to facilitate cell attachment, since cells did not attach to the plastic in its absence (data not 
shown). Serum-starved MCF-7 cells suspended in serum-free medium were seeded on the upper 
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surface and migration was assessed in real-time, with the impedance changes (denoted as Cell Index 
units) occurring whilst cells migrated through the 8 µm-pore membrane measured every 15 minutes 
over 15 hours.  
A substantial increase in cell migration in response to rhIGF-I was observed in comparison to VN 
alone controls (Figure 5A). This increase was similar to that observed for rhIGF-I in the substrate-
bound setup (Figure 4A). In contrast, reduced cell migration was observed in the presence of PEG-
K27, PEG-K65 and PEG-K68 (Figure 5A). Quantitative analysis revealed a migration rate for control 
conditions (VN only) of 0.058 units per 15 h and 0.145 units per 15 h for rhIGF-I (Figure 5B). The 
PEG-IGF-I isomers were less effective (*, p<0.01) compared to rhIGF-I at stimulating cell migration, 
with values of 0.10 units, 0.0945 units and 0.109 units per 15 h recorded for K27, K65 and K68 PEG-
IGF-I isomers, respectively (Figure 5B). Nonetheless, cell migration recorded with solution-phase 
PEG-IGF-I isomers (Figure 5B) was greater than substrate-bound PEG-IGF-I (Figure 4B). 
Taken together, the data from the substrate-bound (Figure 4) and solution-phase setup (Figure 5) 
suggests that the reduced affinity of PEG-IGF-I isomers to both IGFBP-3 and IGF-IR contribute to 
the observed decrease in cell migration.  
3.6 Cell viability induced by rhIGF-I and PEGylated IGF-I isomers 
The potential of IGF-I variants to induce cell viability was assessed on serum starved MCF-7 cells 
exposed to 1 or 100 ng/ml (1.3 or 13 nM) of rhIGF-I or 13 nM of purified PEG-IGF-I isomers (PEG-
K27, PEG-K65 and PEG-K68), suspended in low-serum media (LSM; 0.5% FCS). Cell viability was 
assessed after 72 hours using MTS reagent. For control purposes viability was also assessed in cells 
treated with LSM only. All treatments were observed to equally stimulate cell viability compared to 
the low 1 ng/ml dose of rhIGF-I (Figure 6) and the control treatment (LSM only, not shown). 
Contrasting to the effects observed in cell migration studies, no significant differences were observed 
in the viability induced by the PEG-IGF-I isomers when compared with rhIGF-I. The data are in line 
with our previous observations in other cell lines [29] where PEG-K68 has been shown to stimulate 
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viability and/or proliferation (as assessed using BrDu/thymidine incorporation assay) with the same 
potency as rhIGF-I.  
3.7 Downstream AKT and ERK pathway activation profile of rhIGF-I and PEG-IGF-I isomers 
Previous studies have demonstrated that IGF-I-stimulated cell migration is predominantly mediated 
through the PI3-K/AKT pathway downstream of the IGF-IR activation, with little contribution from 
the ERK/MAPK pathway [5]. Hence, to dissociate the mechanisms between the observed cell 
migration and cell viability effects downstream ERK1/2 and AKT activation (observed through 
phosphorylation) was investigated over 3 hours in response to rhIGF-I and the PEG-IGF-I isomers. In 
line with the previously published studies, rhIGF-I induced a transient activation of up to 15 minutes 
of ERK1/2 and a sustained activation of up to 3 hours of AKT (Figure 7). Furthermore, all PEG-IGF-I 
isomers, including PEG-K27, PEG-K65 and PEG-K68 induced a transient activation of ERK1/2 at 
comparable levels to rhIGF-I (Figure 7). However, in comparison to rhIGF-I AKT activation was 
substantially reduced in cells exposed to the PEG-IGF-I isomers at all the time points tested (Figure 
7). This suggests that the PEG-IGF-I isomers preferentially influence downstream signaling pathways 
such as the PI3-K/AKT pathway while maintaining signaling through the ERK/MAPK pathway.  
4. Discussion 
PEGylation is a process typically employed in order to improve the efficacy of therapeutic proteins by 
extending their in vivo half-life and stability [23, 24]. In the case of IGF-I, the large 40 kDa PEG 
residue mainly inhibits association to its different binding targets, the IGF-IR and the IGFBPs, as 
demonstrated in this manuscript and reported recently [29]. Our data indicate that PEGylation of IGF-
I largely reduces immediate events such as cell migration without affecting long-term events such as 
maintenance of cell viability; this may have implications for the therapeutic use of PEG-IGF-I where 
increased proliferation is desired without eliciting increased migration. We further suggest that the 
increased cell viability maintained in response to PEG-IGF-I isomers could be due to the unaltered 
ERK1/2 activation, whereas the PI3-K/AKT pathway may be implicated in the observed decrease in 
cell migration. 
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In previous studies, we have extensively characterized the potential changes in the potency of IGF-I 
upon the addition of a PEG residue to K68 [29]. These studies identified that the influence of the large 
PEG residue on the biological activity of IGF-I was largely affected its fast association to the IGF-IR 
or IGFBPs. Here, we further investigated the functional implications of the different PEGylation sites 
of IGF-I, namely lysine residues K27, K65 and K68. The activity of all the three PEG-IGF-I isomers 
to activate the IGF-IR was diminished; the most pronounced effects were observed with the K27 
isomer (Figure 2A). This was assessed by the ability of different doses of IGF-I to stimulate IGF-IR 
activation acutely within 15 minutes in 3T3 cells stably expressing IGF-IR. In addition, time course 
experiments over three hours in MCF-7 cells (containing high endogenous levels of IGF-IR) revealed 
two-fold reduced IGF-IR phosphorylation for all the three PEG-IGF-I isomers over the 1 hour and 3 
hour time points tested (Figure 2B). Particularly, PEG-K27 progressed from inducing ~3-fold reduced 
IGF-IR activation over 15 minutes to ~2-fold reduced activation at longer time points (Figure 2B). 
Hence, when lysine residues within IGF-I were PEGylated a slight decrease in their ability to activate 
the IGF-IR was observed, with a more pronounced effect observed for PEG-K27 at 15 minutes 
(Figure 2A and 2B). This data can be further explained by analyzing the previously known structure-
function relationships of IGF-I to its receptor. The IGF-I protein has a domain structure analogous to 
proinsulin [35]. This homology with proinsulin includes the presence of partially conserved B- and A-
domains, an unrelated C-domain and an additional 8 amino acid (AA) C-terminus extension, the D-
domain. Mutational studies investigating the exact site of IGF-I binding to the IGF-IR have shown 
that the amino acid residues Tyr60, Tyr31, Tyr24 (residues 24 and 31 are located in very close 
proximity to K27) of the IGF-I protein are essential for binding to and activating the IGF-IR [36, 37]. 
In addition, substitution of Tyr27 within IGF-II, which shares strong homology with IGF-I, 
completely abolishes binding of IGF-II to the IGF-IR [38]. This suggests that K27 within IGF-I is 
present in the region that may be critically involved in IGF-IR binding and may explain the reduction 
in the ability of PEG-K27 to phosphorylate the IGF-IR. Lysine residues in general are substrates for a 
class of enzymes called ‘transglutaminases’. Recently, these enzymes have shown to be increasingly 
implicated in several major receptor tyrosine kinase signaling pathways [39]. Hence, it could mean 
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that the other lysine residues in IGF-I (K65 and K68) may also bear important significance with 
respect to IGF-I function. 
 
In addition to understanding the ability of PEG-IGF-I isomers to activate the IGF-IR, BIAcore affinity 
binding studies were conducted to determine the affinities of PEG-IGF-I isomers to IGFBPs. These 
experiments revealed that all the three PEG-IGF-I isomers had similar (~10-fold) reduced affinities 
(Kd) to IGFBPs when compared to rhIGF-I. This is highlighted by the reduced association rates but 
unchanged dissociation rates observed between IGFBP and PEG-IGF-I or rhIGF-I (Figure 3). Given 
that the reduced association rate of PEGylated IGF-I to IGFBPs was independent of the site of 
PEGylation, it suggests that steric hindrance by the 40 kDa PEG residue was the origin of this affinity 
shift (~10-fold reduction). These affinity studies indicate that PEGylation of lysine residues partially 
reduces, but not completely abrogates the affinity of IGF-I to its binding partners. Indeed, the data 
suggest that this initial reduction in the affinity of the PEG-IGF-I isomers for the IGFBPs and the 
IGF-IR may mostly impact on fast and immediate anabolic functional effects, but may not affect long-
term functional responses (cell viability). In these latter instances, the PEG-IGF-I isomers may behave 
similarly to rhIGF-I. It is important to recognize and distinguish both the fast and slow anabolic 
activity of IGF-I and their role in various disease conditions. To be used as an effective therapeutic, 
optimal absorption and retention of IGF-I is necessary. Therapeutically relevant application seems to 
be viable with PEG-IGF-I, as it maintains rhIGF-I-like steady-state functionality [29]. Furthermore, it 
was shown that PEG-IGF-I behaves physiologically similarly to rhIGF-I in long term assays such as 
cell proliferation, myoblast differentiation and motor neuron survival [29, 32] up to 5 days in vitro, 
and the improved pharmacokinetic properties provide advantages in muscular as well as neurological 
conditions [21, 29, 32-34].  
 
To test the functional consequences of PEGylating the lysine residues of IGF-I, cell migration as well 
as cell viability was assessed in the presence of these PEG-IGF-I isomers. Previous studies by our 
collaborators have demonstrated that IGF-I interacts with IGFBPs and VN, proteins present 
abundantly in the ECM. Such IGF-I and ECM protein interactions were further shown to 
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synergistically stimulate migration and proliferation in a variety of normal and cancerous epithelial 
cell types [5, 31, 40, 41]. There also exists evidence for such IGF:IGFBP:VN complexes to 
significantly enhance cell functions compared to IGF-I when presented by itself [5]. This suggests that 
the capture of IGF-I to ECM proteins facilitates a concentrated foci of IGF-I in close cellular 
proximity that is able to enhance receptor activation and simultaneously engage the two receptor 
types: the IGF-IR and ECM protein-binding integrins, facilitating cross-talk. Initially, we adopted a 
strategy similar to our collaborators of pre-binding VN, IGFBP-3 and either of the PEG-IGF-I isomers 
to cultureware prior to seeding cells and monitoring cell migration and cell viability. Interestingly 
enough, the pro-migratory effect of rhIGF-I on MCF-7 cells was largely abolished in all PEG-IGF-I 
isomers (Figure 4). This may be attributed to both the reduced affinity to IGFBP-3 that prevented 
IGF-I from being captured into the complex or due to the delayed activation of the IGF-IR by the 
PEG-IGF-I isomers. Indeed, when MCF-7 cells were exposed to the PEG-IGF-I isomers suspended in 
solution, the cell migration remained decreased (Figure 5), suggesting that the delayed IGF-IR 
activation brought about by the PEG-IGF-I isomers resulted in this decreased cell migration. 
However, in the substrate-bound setup (Figure 4) the reduction in cell migration was more profound 
than that observed with PEG-IGF-I in solution-phase. This suggests that it is not merely the delayed 
activation of the IGF-IR but also the reduced association rate to IGFBP-3 that contributed to the 
decreased cell migration observed in the presence of PEG-IGF-I isomers. Indeed, Hollier et al. [5] 
have demonstrated that using IGF-I analogs that have reduced affinity for IGFBPs form IGF-
I:IGFBP:VN complexes only weakly and have reduced migratory effects compared to native IGF-I. In 
contrast to migration, all PEG-IGF-I isomers supported MCF-7 cell viability at levels similar to that 
induced by rhIGF-I (Figure 6), which confirms previous studies performed by us in other human, rat 
and canine cell lines [29]. This may be in part due to specific signaling mechanisms downstream of 
the IGF-IR being involved.  
 
Indeed, PI3-K/AKT and MAPK/ERK pathways are among the most well characterized signaling 
pathways downstream of IGF-IR activation. In particular relevance to this manuscript, previous 
studies using chemical inhibitors directed against either of these pathways have demonstrated the 
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preferential involvement of the PI3-K/AKT pathway in driving cell migration [5] and the 
MAPK/ERK pathway in driving cell proliferation in response to IGF-I [42]. Correspondingly, the 
reduction in cell migration observed in our studies was accompanied by a concomitant reduction in 
AKT activation in response to PEGylated IGF-I. In contrast, rhIGF-I demonstrated increased cell 
migration and consequently, sustained AKT activation. Analysis of the MAPK/ERK pathway 
revealed consistent activation of ERK1/2 tested across all PEGyated as well as recombinant IGF-I 
isomers. Indeed, this was accompanied by the increased cell viability observed for rhIGF-I as well as 
all the PEG-IGF-I isomers. Furthermore, these findings are in line with our previous observations [29] 
of short-term MAPK and AKT activation by PEG-IGF-I. Further studies using inhibitors targeting 
each of these pathways will help confirm the involvement of these pathways in regulating the specific 
biological functions of the PEG-IGF-I isomers. Also, an additional aspect to consider for explaining 
the differences in cell migration and viability observed in response to the PEG-IGF-I isomers, is the 
markedly different nature of these two biological effects. Migration is a cellular process that greatly 
depends on the response of migrating cells to the biomechanical properties of the neighboring 
microenvironment. This is especially critical in cancer where migration of cells through the 
connective tissue microenvironment happens in a fast and efficient manner. The reduced affinity of 
PEG-IGF-I isomers to the IGF-IR, IGFBPs and possibly other components of the ECM could result in 
PEG-IGF-I being unable to be scaffolded within the focal adhesion contacts that are known to 
stimulate downstream signaling events that facilitate cell migration [43]. In contrast to migration, 
induction of metabolic functions during cell proliferation is a largely cell-intrinsic response as 
consequence of an appropriate external growth stimulus, which may not rely heavily on the 
extracellular interaction for its execution. As such, it is expected that PEGylation maintains the long-
term functional effects of IGF-I, such as processes controlling mitotic events.  
IGF-I has been therapeutically used in multiple disease conditions such as muscular and neuronal 
diseases [24], and several catabolic and cachexia conditions including cancer cachexia [44]. On the 
other hand, strategies to inhibit the IGF-I pathway have been exploited clinically in cancer [45], given 
the pro-proliferative and pro-metastatic activity of IGF-I [46]. Aggressive phenotypes in cancer are 
often linked to increased expression and activation of the IGF-IR. The IGF-IR is involved in IGF-I- 
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and IGF-II-mediated mitogenic signaling cascades and is also linked to development and progression 
of malignancy [45]. IGF-IR has been shown to induce EMT (epithelial to mesenchymal transition) 
through the involvement of insulin receptor substrate (IRS) and phosphotidyl-inositol-3 kinase (PI3K) 
[47, 48]. EMT is a phenomenon which leads to increased migration and invasion of cancer cells, 
thereby leading to metastasis and establishment of secondary tumor sites [49]. Given the lack of cell 
migratory capabilities of the PEGylated IGF-I, the PEG-IGF-I isomers could be used as a possible 
therapy options in cancer, where excess PEG-IGF-I isomers can be used to dilute out the  native IGF-I 
to compensate for the increased cell migration fostered by the endogenous IGF-I. Given the extensive 
involvement of the IGF system in inducing EMT in a wide range of cancers, the restricted effect on 
breast cancer cell migration by PEG-IGF-I isomers greatly enhances its significance in such a critical 
disease condition. However, further studies need to be performed to understand the mechanisms 
underpinning the decreased migratory effects observed in PEG-IGF-I isomers. 
 
Given that the PEG-IGF-I isomers retain a majority of the long-term biological functions of native 
IGF-I (cell proliferation, myoblast differentiation, motor neuron survival [29, 34]) they can also be 
used to treat disease conditions such as muscular dystrophy, muscle wasting and IGF deficiency-
induced short stature. Lack of muscle growth/proliferation is the key determinant in these conditions 
[22, 50], which can be subverted using exogenously added PEG-IGF-I. Furthermore, PEG-IGF-I 
isomers may also find use in repairing cutaneous tissue damaged post-exposure to harmful irradiations 
such as ultra violet rays. 
 
In summary, this study provides evidence that PEGylation of IGF-I affects IGF-I-mediated cell 
migration without compromising IGF-I’s long term functionality. It is possible that such long-acting 
PEG-IGF-I isomers may be used in disease states where excess IGF-I can be beneficial (e.g. muscular 
atrophy, neurodegenerative disorders, sun burn) or where IGF-I-mediated migration is detrimental 
(IGF-I-dependent epithelial cancers). Indeed, future studies into the use of PEG-IGF-I isomers on 
animal models recapitulating the disease states outlined above will provide additional vigor to these 
arguments.  
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Figure legends: 
Figure 1: Analytical IEC-HPLC and SDS PAGE of PEG-IGF-I isomers. Pure positional isomers 
were separated from 10 mg PEGylation mixture using a preparative strong-cation exchange column 
(TOSOH-BIOSEP, SP-5PW). A., Five different peak fractions (numbered 0-4) were isolated and 
processed for further analysis. B., The purified peak fractions 0-4 were electrophoresed by 4-12% 
Tris-glycine SDS-PAGE under non-reduced (left) and reduced (right) conditions and gels were 
stained for protein with Coomassie blue. MW, molecular weight marker. 
Figure 2: IGF-IR phosphorylation stimulated by rhIGF-I and PEG-IGF-I isomers. A., NIH-3T3 
cells stably transfected with the human IGF-IR were serum-starved overnight and incubated with 
doses of up to 1.3 µM of rhIGF-I or PEG-IGF-I isomers (PEG-K27, PEG-K65, PEG-K68) for 15 
minutes. Subsequently, cells were processed for in-cell analysis as described in Methods. The IGF-IR 
phosphorylation signal was normalised for total IGF-IR levels for the given treatment. The IGF-IR 
phosphorylation signal was normalized for total IGF-IR levels for the given treatment. Data points 
show means ± SEM of 6-12 measurements from 3-4 independent experiments and were fitted to a Hill 
binding eq. B., Serum-starved MCF-7 cells were incubated with or without 13 nM rhIGF-I or PEG-
IGF-I isomers over 3 h and the IGF-IR phosphorylation was assessed as outlined above. ***p < 
0.001; *p < 0.05; **p < 0.01 vs. untreated control. 
Figure 3: Interaction of rhIGF-I and PEG-IGF-I isomers with IGFBPs. BIAcore analysis was 
performed with immobilized IGFBP’s and chips were probed with increasing concentrations of 
rhIGF-I or PEG-IGF-I isomers PEG-K27, PEG-K65 and PEG-K68 at 1.25-100 nM. The obtained 
time constants kon were plotted against koff (BP-1, inverted triangle; BP-2, diamond; BP-3, square; BP-
4, upright triangle; BP-5, circle). Note that the affinity shifts were always in clusters independent of 
the PEGylation site (circles) and mostly restricted to reductions in kon rather than koff. Data for rhIGF-I 
and PEG-K68 (*) are reproduced with permission from Metzger et al. 2011. 
Figure 4: Effects of substrate-bound rhIGF-I and PEG-IGF-I isomers on MCF-7 cell migration. 
Migration of MCF7 cells was assessed in response to rhIGF-I, PEG-K27, PEG-K65 or PEG-K68 
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given as VN:IGFBP-3:(PEG-)IGF-I complex on the xCELLigence platform as described in Methods. 
Changes in impedance at the under-surface of the membranes resulting from cell migration were 
measured and recorded every 15 minutes over 15 hours. A., time course of Cell Index over 15 h. B., 
quantitative analysis of migration rate (slopes over 15 h). Statistical analysis was performed by 
ANOVA and Dunnet’s post-hoc test comparing all experimental groups against rhIGF-I. ***, 
p<0.001. 
Figure 5: Effects of rhIGF-I and PEG-IGF-I isomers suspended in solution on MCF7 cell 
migration. Migration of MCF7 cells was assessed in response to rhIGF-I, PEG-K27, PEG-K65 or 
PEG-K68 suspended in solution-phase on the xCELLigence platform as described in Methods. VN 
was added to all treatments to facilitate cell attachment. Changes in impedance at the under-surface of 
the membranes resulting from cell migration were measured and recorded every 15 min over 15 h. A., 
time course of Cell Index over 15 h. B., quantitative analysis of migration rate (slopes over 15 h). for 
statistical analysis, ANOVA was performed followed by Dunnet’s post-hoc test comparing all 
experimental groups against rhIGF-I or against VN only. ***, p<0.001. *, p<0.05; **, p<0.01. 
Figure 6: Effects of rhIGF-I and PEG-IGF-I isomers on MCF-7 cell viability. Viability of MCF7 
cells was assessed in response to rhIGF-I, PEG-K27, PEG-K65 or PEG-K68 using MTS as described 
in Methods. Statistical analysis was performed by ANOVA and Dunnet’s post-hoc test comparing all 
experimental groups against rhIGF-I 100 ng/ml. ***, p<0.001.  
Figure 7: PEG-IGF-I-mediated activation of ERK/MAPK and PI3-K/AKT pathways. Serum-
starved MCF-7 cells were incubated with rhIGF-I or PEG-IGF-I isomers for the indicated times. Cells 
were then lysed and levels of phosphorylated AKT and ERK1/2 were determined by immunoblot 
analysis. Membranes were subsequently stripped and re-probed to determine the total levels of AKT 
and ERK1/2. Representative blots from multiple experiments are shown. 
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FIGURE 4 
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FIGURE 5 
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 FIGURE 6 
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FIGURE 7 
 
 
